Chord Therapeutics adds Claudio Nessi and Francesco Draetta to its Board along with receiving $16m Series A financing from Omega Funds
– SWITZERLAND, Geneva – Chord Therapeutics, a clinical-stage biopharmaceutical company developing drugs for rare diseases, today announced the closing of a $16 million Series A financing from Omega Funds.…